SCHEMBL123203

SCHEMBL123203

CCc1ccncc1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 15/20 0.51
KDM6B O15054 7/20 0.51
KDM4D Q6B0I6 3/20 0.50
TDP1 Q9NUW8 2/20 0.50
KDM4E B2RXH2 2/20 0.50
KDM4A O75164 2/20 0.50
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPT P10636 1/20 0.50
THRB P10828 1/20 0.50
KMT2A Q03164 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
GABRP O00591 2/20 0.49
GABRD O14764 2/20 0.49
GABRA1 P14867 2/20 0.49
GABRB1 P18505 2/20 0.49
GABRG2 P18507 2/20 0.49
GABRB3 P28472 2/20 0.49
GABRA5 P31644 2/20 0.49
GABRA3 P34903 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30465694 1.00 KDM4C (0.51) KDM4CKDM6BKDM4DTDP1KDM4E
Acetic Acid SCHEMBL16666943 0.96 KDM4C (0.49) KDM4CKDM6BKDM4DTDP1KDM4E
SCHEMBL258369 0.87 KDM4C (0.51) KDM4CKDM6BKDM4DTDP1KDM4E
Hydrochloric Acid SCHEMBL5739434 0.85 KDM4C (0.50) KDM4CKDM6BKDM4DTDP1KDM4E
SCHEMBL115648 0.84 KDM4C (0.56) KDM4CKDM6BKDM4DTDP1KDM4E
SCHEMBL3880004 0.84 KDM4C (0.50) KDM4CKDM6BKDM4DTDP1KDM4E
SCHEMBL30100781 0.84 KDM4C (0.56) KDM4CKDM6BKDM4DTDP1KDM4E
SCHEMBL3818724 0.84 TDP1 (0.44) KDM4CKDM6BKDM4DTDP1KDM4E
SCHEMBL4005290 0.84 GABRP (0.55) KDM4CKDM6BKDM4DTDP1KDM4E
SCHEMBL2370442 0.83 KDM4C (0.46) KDM4CKDM6BKDM4DTDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118525087-A Lipase formulations and methods thereof 第一浪潮生物制药有限公司 2024-08-20 CN claimed
CN-116437947-A Non-pig formulations and methods thereof 第一浪潮生物制药有限公司 2023-07-14 CN claimed
EP-2788323-B1 NEW PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VILDAGLIPTIN CHEMELECTIVA SRL (IT) 2017-01-11 EP claimed
EP-2788323-A1 NEW PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VILDAGLIPTIN Chemelectiva Srl. (IT) 2014-10-15 EP claimed
WO-2013083326-A1 NEW PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VILDAGLIPTIN CHEMELECTIVA S.R.L. (IT) 2013-06-13 WO claimed
US-7887840-B2 Bioavailability of low- solubility drugs BEND RESEARCH, INC. (US) 2011-02-15 US claimed
EP-2275091-A1 Pharmaceutical compositions comprising adsorbates of an amorphous drug Pfizer Products Inc. (US) 2011-01-19 EP claimed
US-20040147491-A1 Prevent, maintenance of Dna damage; administering compound which forms nicotinamide-adenine dinucleotide NIADYNE, INC. 2004-07-29 US claimed
US-20010033848-A1 Adjustment of cellular nicotinamide-adenine dinucleotide NIADYNE, INC. 2001-10-25 US claimed
EP-1143954-A2 USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS University of Kentucky Research Foundation (US) 2001-10-17 EP claimed
WO-2000032179-A2 USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2000-06-08 WO claimed
US-5259992-A Cuprous iodide-pyridine derivative complex REXHAM GRAPHICS INC. (US) 1993-11-09 US claimed
EP-0117080-B1 SKIN TREATMENT COMPOSITION UNILEVER PLC (GB) 1992-04-08 EP claimed
US-12595245-B2 Inhibitors of MET kinase CELYN THERAPEUTICS, INC. (US) 2026-04-07 US disclosed
CN-121779373-A Synthesis method of imazethapyr 辽宁优创植物保护有限公司 2026-04-03 CN disclosed
EP-4192833-B1 PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES RICHTER GEDEON NYRT (HU) 2026-01-21 EP disclosed
US-4576755-A Water-soluble fibre-reactive phthalocyanine compounds HOECHST AKTIENGESELLSCHAFT (DE) 1986-03-18 US disclosed
EP-0075905-B1 WATER-SOLUBLE REACTIVE PHTHALOCYANINE COMPOUNDS; PROCESS FOR THEIR PREPARATION AND THEIR USE AS DYESTUFFS HOECHST AKTIENGESELLSCHAFT (DE) 1986-01-15 EP disclosed
EP-0075905-A2 Water-soluble reactive phthalocyanine compounds; process for their preparation and their use as dyestuffs HOECHST AKTIENGESELLSCHAFT (DE) 1983-04-06 EP disclosed
US-4237050-A Process for the preparation of water-soluble phthalocyanine dyestuffs HOECHST AKTIENGESELLSCHAFT (DE) 1980-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595245-B2 Inhibitors of MET kinase MET, ABL1, ERBB2 KDM4C 721/4885KDM6B 518/4885KDM4D 608/4885
US-20040147491-A1 Prevent, maintenance of Dna damage; administering compound which forms nicotinamide-adenine dinucleotide NQO1, NNT, NAMPT KDM4C 3353/4885KDM6B 3566/4885KDM4D 2995/4885
US-20010033848-A1 Adjustment of cellular nicotinamide-adenine dinucleotide NQO1, NNT, NAMPT KDM4C 3290/4885KDM6B 3163/4885KDM4D 3036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.